Celgene Meets on the Top Line, Misses Where It Counts
Celgene (NAS: CELG) reported earnings on Jan. 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Celgene met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly, and GAAP earnings per share expanded significantly.
Gross margins expanded, operating margins contracted, net margins expanded.
Celgene recorded revenue of $1.28 billion. The 17 analysts polled by S&P Capital IQ predicted revenue of $1.28 billion. Sales were 20% higher than the prior-year quarter's $1.07 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $1.05. The 25 earnings estimates compiled by S&P Capital IQ predicted $1.06 per share on the same basis. GAAP EPS of $0.81 for Q4 were 107% higher than the prior-year quarter's $0.44 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 94.0%, 130 basis points better than the prior-year quarter. Operating margin was 29.6%, 90 basis points worse than the prior-year quarter. Net margin was 31.9%, 1,230 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.31 billion. On the bottom line, the average EPS estimate is $1.12.
Next year's average estimate for revenue is $5.52 billion. The average EPS estimate is $4.83.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,454 members out of 1,505 rating the stock outperform, and 52 members rating it underperform. Among 394 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 379 give Celgene a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Celgene is outperform, with an average price target of $74.83.
The biotechnology and health-care investing landscape is littered with also-rans and a few major winners. Is Celgene the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Celgene to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.